Literature DB >> 31701393

Hepatocellular carcinoma and non-alcoholic fatty liver disease.

Pegah Golabi1,2, Logan Rhea1, Linda Henry2, Zobair M Younossi3,4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the most common liver disorder worldwide, affecting 25.2% of the general population. In fact, NAFLD is among the most common etiologies for hepatocellular carcinoma (HCC). The burden of NAFLD is primarily driven by the epidemic of obesity and type 2 diabetes which are expected to worsen throughout the world. In this context, the burden of NAFLD and associated HCC and cirrhosis are also expected to increase. Despite its growing disease burden, diagnostic tools and treatment modalities remain very limited. This conundrum of increasing prevalence and limited treatment options will be reflected as increasing number of NAFLD-related cirrhosis and HCC cases. This article reviews the most updated information about NAFLD-related HCC and provides some insight into strategies that must be considered to reduce its potential disease burden.

Entities:  

Keywords:  Cirrhosis; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis

Mesh:

Year:  2019        PMID: 31701393     DOI: 10.1007/s12072-019-09995-8

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  75 in total

Review 1.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

2.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 4.  The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.

Authors:  Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2014-01-21       Impact factor: 10.864

5.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

6.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

7.  Hepatocellular carcinoma in patients with cryptogenic cirrhosis.

Authors:  Edoardo Giovanni Giannini; Elisa Marabotto; Vincenzo Savarino; Franco Trevisani; Maria Anna di Nolfo; Paolo Del Poggio; Luisa Benvegnù; Fabio Farinati; Marco Zoli; Franco Borzio; Eugenio Caturelli; Maria Chiaramonte
Journal:  Clin Gastroenterol Hepatol       Date:  2009-05       Impact factor: 11.382

8.  Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.

Authors:  Nwe Ni Than; Anwar Ghazanfar; James Hodson; Nadeem Tehami; Chris Coldham; Hynek Mergental; Derek Manas; Tahir Shah; Philip N Newsome; Helen Reeves; Shishir Shetty
Journal:  QJM       Date:  2017-02-01

Review 9.  The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease.

Authors:  Francesco Massimo Perla; Maurizia Prelati; Michela Lavorato; Daniele Visicchio; Caterina Anania
Journal:  Children (Basel)       Date:  2017-06-06

10.  TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Authors:  Yang-Lin Liu; Helen L Reeves; Alastair D Burt; Dina Tiniakos; Stuart McPherson; Julian B S Leathart; Michael E D Allison; Graeme J Alexander; Anne-Christine Piguet; Rodolphe Anty; Peter Donaldson; Guruprasad P Aithal; Sven Francque; Luc Van Gaal; Karine Clement; Vlad Ratziu; Jean-Francois Dufour; Christopher P Day; Ann K Daly; Quentin M Anstee
Journal:  Nat Commun       Date:  2014-06-30       Impact factor: 14.919

View more
  13 in total

1.  Estrogen Deficiency Aggravates Fluoride-Induced Liver Damage and Lipid Metabolism Disorder in Rats.

Authors:  Ya-Ming Yu; Bian-Hua Zhou; Yi-Lin Yang; Cheng-Xiang Guo; Jing Zhao; Hong-Wei Wang
Journal:  Biol Trace Elem Res       Date:  2021-08-15       Impact factor: 3.738

2.  Impact of Metabolic Dysfunction Associated Fatty Liver Disease on the Prognosis of Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma Based on Propensity Score Matching Analysis.

Authors:  Jiao Xue; Qing-Xia Wang; Huan-Ming Xiao; Mei-Jie Shi; Yu-Bao Xie; Sheng Li; Ming Lin; Xiao-Ling Chi
Journal:  Cancer Manag Res       Date:  2022-07-14       Impact factor: 3.602

3.  Structure based innovative approach to analyze aptaprobe-GPC3 complexes in hepatocellular carcinoma.

Authors:  Woo-Ri Shin; Dae-Young Park; Ji Hun Kim; Jin-Pyo Lee; Nguyen Quang Thai; In-Hwan Oh; Simranjeet Singh Sekhon; Wooil Choi; Sung Yeon Kim; Byung-Kwan Cho; Sun Chang Kim; Jiho Min; Ji-Young Ahn; Yang-Hoon Kim
Journal:  J Nanobiotechnology       Date:  2022-04-27       Impact factor: 9.429

4.  Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma.

Authors:  Huancheng Wang; Jia Liu
Journal:  Front Genet       Date:  2020-10-08       Impact factor: 4.599

Review 5.  Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Massimo G Colombo
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

6.  Assessment of Prognostic Value of Aspartate Aminotransferase-to-Platelet Ratio Index in Patients With Hepatocellular Carcinoma: Meta-Analysis of 28 Cohort Studies.

Authors:  XinYue Zhang; Zhen Svn; MengSi Liv; MengNan Liu; YiHan Zhang; Qin Sun
Journal:  Front Med (Lausanne)       Date:  2021-11-26

Review 7.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

Review 8.  The Crosstalk between Tumor Cells and the Microenvironment in Hepatocellular Carcinoma: The Role of Exosomal microRNAs and their Clinical Implications.

Authors:  Devis Pascut; Muhammad Yogi Pratama; Niem V T Vo; Rina Masadah; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2020-03-29       Impact factor: 6.639

Review 9.  Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.

Authors:  Yi-Wen Shi; Rui-Xu Yang; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

10.  Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.

Authors:  Jian Xu; Xiaomin Shen; Bo Zhang; Rui Su; Mingxuan Cui; Lihua Yan; Yu Cao
Journal:  Biosci Rep       Date:  2021-09-30       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.